Dr. Pazdur and his allies like to suggest that accelerated-approval advocates risk throwing science out the window. But in truth, there's no scientific reason to believe that large placebo-controlled trials -- in which treatments are tested against nothing, i.e., the proverbial sugar pill -- should be considered the "gold standard," as Dr. Pazdur believes. Withholding treatment is unethical in terminal diseases, and we have enough historical data about how cancer patients fare to judge new treatments without the need for placebo control groups.
Lets hope he a man of his words.
Lets hope he a man of his words.
Recent SNGX News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/28/2026 09:21:17 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/28/2026 09:20:17 PM
- Suitability of Vaccine Platform for Bundibugyo Virus, Cause of the Ebola Outbreak in Congo • PR Newswire (US) • 05/26/2026 11:30:00 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 05/08/2026 08:16:15 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 05/08/2026 08:14:13 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 05/08/2026 08:12:12 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 05/08/2026 08:10:14 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/08/2026 08:05:35 PM
- Soligenix Announces Recent Updates and First Quarter 2026 Financial Results • PR Newswire (US) • 05/08/2026 11:30:00 AM
- SNGX Phase 3 Trial Halted on HyBryte • IH Market News • 04/28/2026 03:06:46 PM
- SNGX Phase 3 Trial Halted — HyBryte Setback Puts Strategy in Question • IH Market News • 04/28/2026 03:06:46 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/28/2026 11:30:13 AM
- Soligenix Announces Interim Results from the Phase 3 FLASH2 Trial Evaluating HyBryte™ in Treatment of Cutaneous T-Cell Lymphoma • PR Newswire (US) • 04/28/2026 11:30:00 AM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/03/2026 04:15:15 AM
- Positive Clinical Results from HyBryte™ Comparative Study Evaluating HyBryte™ Against Valchlor® in the Treatment of Cutaneous T-Cell Lymphoma Published in Oncology and Therapy • PR Newswire (US) • 04/02/2026 11:30:00 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 03/31/2026 08:13:29 PM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 03/31/2026 08:11:25 PM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 03/31/2026 08:09:30 PM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 03/31/2026 08:08:14 PM
- Soligenix Announces Recent Accomplishments and Year End 2025 Financial Results • PR Newswire (US) • 03/31/2026 11:30:00 AM
- Soligenix secures EU orphan drug designation for Behçet’s disease therapy • IH Market News • 03/26/2026 02:15:07 PM
- Soligenix Receives Orphan Drug Designation from the European Commission for SGX945 for the Treatment of Behçet's Disease • PR Newswire (US) • 03/26/2026 11:30:00 AM
